Key Highlights
- Novocuff raises $26M Series A, led by AXA IM Alts.
- Funding supports U.S. pivotal clinical trial and commercialization.
- New board members from AXA IM Alts and Laerdal Million Lives Fund.
- Novocuff’s device aims to reduce preterm birth risks.
Source: Business Wire
Notable Quotes
- “We are thrilled to have the support of a strong and mission-aligned group of investors as we enter this exciting next phase of clinical development. This funding catalyzes our ability to deliver a solution to a healthcare need for women, and their families and healthcare providers.” — Amelia “Amy” Degenkolb, CEO & Co-founder at Novocuff
- “Our investment should enable completion of a U.S. pivotal trial and the introduction of the Novocuff device to global markets, including low- and middle-income countries.” — Curt LaBelle, Head of Healthcare Private Equity at AXA IM Alts
- “Tragically, preterm birth is the number one cause of infant mortality globally. We are now looking forward to partnering with mission-aligned investors like AXA IM Alts to continue to work toward this goal.” — Becca Shmukler, Principal at the Laerdal Million Lives Fund
SoHC's Take
Novocuff’s successful Series A funding marks a significant milestone in addressing preterm birth, a critical global health issue. The strong backing from prominent investors like AXA IM Alts and the Laerdal Million Lives Fund underscores the medical community’s confidence in Novocuff’s innovative approach. With the new funds, Novocuff is well-positioned to advance its clinical trials and bring its groundbreaking device to market, potentially transforming the standard of care for women at risk of preterm birth. This development is a promising step forward in reducing infant mortality and improving pregnancy outcomes worldwide.
